CMC Biopharmaceuticals A/S And Resistentia AB Announce A Development And Manufacturing Agreement
10/19/2005 5:09:18 PM
CMC Biopharmaceuticals A/S (CMC), a Copenhagen-based contract manufacturing organization, and Resistentia Pharmaceuticals AB, a drug development company based in Uppsala, Sweden today announced that they have entered into a development and manufacturing agreement for the cGMP production of a fusion protein. The product which is an immunotherapeutic reagent used for the treatment of IgE-mediated allergies will be manufactured at CMC’s facility in Copenhagen.
comments powered by